Wyeth has a long-standing tradition of donating pharmaceutical products and vaccines to developing nations in response to health care emergencies as well as the chronic needs of medically underserved populations. Pharmaceutical donations have included anti-infectives, anti-fungals and analgesics.

In 2002 a WHO study involving 40,000 South African children showed that a new pneumococcal vaccine developed by Wyeth could save the lives of 500,000 children yearly in poor countries. Until now, no vaccine was available to protect against pneumonia, the leading cause of death of children worldwide, killing about 4 million per year. The vaccine reduced the incidence of pneumonia by more than 20 percent overall. It also reduced the incidence of invasive pneumococcal disease by more than 80 percent in children not infected with HIV and more than 50 percent in those with HIV. Also participating in the study was the South African Medical Research Council.

Wyeth is also helping fund the provision of the newly developed pneumococcal conjugate vaccine for a five-year clinical trial in the Gambia, as part of one of the largest clinical trials of its kind in a developing country. The Medical Research Council (U.K.) is conducting this study in cooperation with the Gates Foundation, the National Institutes of Health (U.S.), U.S. Agency for International Development (USAID), the WHO and others.

For more information, visit: www.wyeth.com